Abstract: One or more example embodiments of the present invention relates to a computer-implemented method for assessing a component quality of an electron emitter as a function of an ascertained degree of similarity with at least one further electron emitter.

Abstract: The present invention relates to a method for treating a skin disease responsive to modulation of premature translation termination, comprising administering to a mammalian patient in need thereof an effective amount of clitocine as a composition for topical use comprising the compound and a pharmaceutically acceptable carrier or diluent. The topical treatment is surprisingly effective and has less side effects than known treatments. The present invention further relates to a method for modulating premature translation termination in a mammalian skin cell, comprising contacting a mammalian skin cell exhibiting premature translation termination with an effective amount of clitocine as a composition for topical use comprising the compound and a pharmaceutically acceptable carrier or diluent.

Abstract: A rotary piston X-ray source including a housing, a rotary piston X-ray source, and a magnetic deflection unit. The rotary piston X-ray source is mounted inside the housing to be rotatable about an axis of rotation relative to the housing. The magnetic deflection unit includes at least one multipole and is disposed outside the rotary piston. The at least one multipole has at least four magnetic poles, which are disposed about the axis of rotation and include coil windings. The magnetic poles further define a multipole plane on which a central axis of the at least one multipole is perpendicularly centered, and the at least one multipole is arranged such that the central axis of the at least one multipole and the axis of rotation span a surface.

Abstract: One or more example embodiments of the present invention relates to a computer-implemented method for assessing a component quality of an electron emitter as a function of an ascertained degree of similarity with at least one further electron emitter.

Abstract: The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL35 (rpL35/rpL29)-dependent translation of at least one mRNA in a mammalian cell. The mRNA may comprise a premature termination codon (PTC), undergoes premature translation termination, causes programmed ?1 ribosomal frame shifting (?1PRF), or is a polycistronic mRNA. Furthermore a respective screening system, methods of treating or preventing a disease or condition, and compounds that modulate the rpL35 (rpL35/rpL29)-dependent translation, in particular atazanavir or derivatives thereof and artemisinin or artesunate or derivatives thereof are provided.